Deutsche Bank raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $90 from $56 and keeps a Buy rating on the shares. The company reported “strongly positive” data from the Phase 3 X-TOLE2 trial of azetukalner in focal-onset seizures, the analyst tells investors in a research note. The firm firm views the readout as a “best case scenario.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals Launches $500 Million Public Share Offering
- Xenon Pharmaceuticals announces $500M common shares offering
- Xenon Pharmaceuticals price target raised to $100 from $65 at Jefferies
- Xenon Pharmaceuticals price target raised to $80 from $59 at RBC Capital
- Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate